Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 2 of 2

TitleType
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All